Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genprex, Inc. - Common Stock (NQ:GNPX)

9.000 -2.500 (-21.74%)
Streaming Delayed Price Updated: 10:46 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Genprex (GNPX) Stock Moves on Promising Diabetes Treatment Data
Genprex (GNPX) stock is on the move Thursday after providing investors with an update on a clinical trial of its diabetes treatment. 
Via InvestorPlace
Why Enovix Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at all the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Inks Deal with University of Pittsburgh for Exclusive License to Diabetes Technology
Via Investor Brand Network
Topics Intellectual Property
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
 
Via Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Gene Therapy Treatment Data to be Presented at Upcoming International Diabetes Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial, Licenses Additional Technology from University of Pittsburgh
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Gene Therapies for Cancer and Diabetes at Upcoming Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Upcoming Investor, Industry Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy
Via Investor Brand Network
Topics Intellectual Property
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New... 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial to Higher Dose
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in June Investor Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment
Via Investor Brand Network
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference
Via Investor Brand Network
Genprex to Participate in Upcoming Investor Conference in March
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.